N-terminal site selective inhibitors of human angiotensin conversion enzyme (ace)
CA 2335918 A1 · Owner: Institut National De La Sante Et De La Recherche Medicale (Inserm) · Inventors: Menard, Joel; Ezan, Eric; Chauvet, Marie-Therese
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns peptide derivatives useful as N-terminal site selective inhibitor of the human angiotensin conversion enzyme. Said derivatives comprise the amino acid sequence of the following formula: -Asp-Phe-?(PO¿2?CH¿2?)-Ala-Xaa'- wherein: ?(PO¿2?CH¿2?) indicates that the peptide bond (CONH) between Phe and Ala has been replaced by the phosphonic bond PO¿2?CH¿2?; and Xaa' represents an amino acid residue. Said derivatives can be used in pharmaceutical compositions in particular for protecting hematopoietic strain cells of patients subjected to aggressive chemotherapeutic or radiotherapy treatment.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 1, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 1, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 1, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.